List of Dalvance drug patents
Dalvance is owned by Allergan.
Dalvance contains Dalbavancin Hydrochloride.
Dalvance has a total of 4 drug patents out of which 0 drug patents have expired.
Dalvance was authorised for market use on 23 May, 2014.
Dalvance is available in powder;intravenous dosage forms.
Dalvance can be used as treatment of bacterial infections using a two-dose regimen of dalbavancin..
Drug patent challenges can be filed against Dalvance from 2023-05-24.
The generics of Dalvance are possible to be released after 23 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months from now) | |
| US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months from now) | |
| US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(5 months from now) | |
| US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
| New Patient Population (NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 2023-05-24
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic